Startups

Medical device startup ReGelTec raises $3.75M, reports clinical progress despite pandemic

The company, which is led by former Harpoon Medical CEO Bill Niland, is conducting trials in Colombia.

ReGelTec's implants in place. (Courtesy photo)

Baltimore medical device startup ReGelTec is conducting a trial on patients and reporting new $3.75 million in funding as it develops a treatment for chronic low back pain.

It’s a couple notes of 2020 progress from the Camden Yards-based startup, which is helmed by longtime medtech executive Bill Niland and execs who led Baltimore startup Harpoon Medical to $100 million-plus acquisition by Edwards Lifesciences. (Along with having experience in building medical device companies, Niland also has experience with back pain, having had three degenerated discs and multiple procedures over the years.) The technology was invented by Dr. Anthony Lowman, and Niland determined it was at a point where it was ready for the clinic.

As with any medical technology, however, getting to that point will require showing proof of its safety and effectiveness. ReGelTec is currently conducting an early feasibility study in Barranquilla, Colombia. This involves treating patients with degenerative disc disease with the company’s hydrogel. Called HYDRAFIL, the gel is injected into the nucleus of a disc, then cools to form an implant. This is designed to ease pain, and restore parts of the disc that were lost.

Bill Niland

Bill Niland. (Courtesy photo)

So far, 11 patients underwent the procedure. With ReGelTec overseeing remotely via Zoom, they were awake and under local anesthesia, and were up and walking within an hour or two, per info from the company. Its statement said patients reported “significant pain reduction and improvements in functional status at 30-days.” Dr. Douglass Beall, chairman of the company’s advisory board, called the results “very promising.”

ReGelTec will continue this study with nine more patients, and expects to finish enrollment by the end of October.

The company raised new funding in order to continue this trial and work toward clinical trials in the U.S. The $3.75 million Series A included participation from Baltimore’s Abell Foundation, which earned a 10-time return on Harpoon, and angel investors, Niland said.

“The COVID-19 pandemic has added complexity and additional challenges to conducting the early clinical work, which makes our clinical results even more exciting,” Niland said.

Companies: Harpoon Medical / Abell Foundation

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

Trump may kill the CHIPS and Science Act. Here’s what that means for your community.

Despite big raises and contracts, a tech training giant lays off staffers and loses its CEO

14 tech community events to be thankful for in November

How 4 orgs give back to their local tech community

Technically Media